Arbutus Biopharma Corporation (ABUS)
Summary
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creating significant legal optionality. ABUS's valuation is driven by its hepatitis B pipeline, especially imdusiran, with clinical milestones outweighing speculative legal outcomes. Recent financials show a narrowed net loss and 1.5-year cash runway, reflecting cost reductions and focused R&D.
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.11 per share a year ago.
Arbutus Biopharma Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BG Bart Gancher Intech Investment Management LLC | 33,574 | $147,630.94 | $150,915.13 | $3,284.19 | 2.22% |
 Joseph Castro Nuveen LLC | 259,017 | $865,883.84 | $1.16M | $297,361.51 | 34.34% |
 Li Peng China Universal Asset Management Co. Ltd. | 34,129 | $114,265.56 | $155,969.53 | $41,703.97 | 36.5% |
| ECD Elizabeth C. DeWan WMG Financial Advisors LLC | 12,605 | $34,159.55 | $57,730.9 | $23,571.35 | 69% |
| SC Stephen Cheifetz Kades & Cheifetz LLC | 20,000 | $40,600 | $94,590 | $53,990 | 132.98% |
Arbutus Biopharma Corporation (ABUS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arbutus Biopharma Corporation ever had a stock split?
Arbutus Biopharma Corporation Profile
| Biotechnology Industry | Healthcare Sector | Lindsay Androski CEO | NASDAQ (NGS) Exchange | 03879J100 CUSIP |
| US Country | 19 Employees | - Last Dividend | 4 Nov 2010 Last Split | 3 Aug 2015 IPO Date |
Overview
Arbutus Biopharma Corporation, originally known as Tekmira Pharmaceuticals Corporation until its rebranding in July 2015, is a biopharmaceutical entity involved in the development of innovative treatments for the chronic Hepatitis B virus (HBV) infection primarily within the United States. Headquartered in Warminster, Pennsylvania, Arbutus is dedicated to pioneering new therapeutics that promise a brighter future for individuals battling HBV. Their scientific endeavors extend beyond HBV, venturing into small molecule antiviral medicines aimed at various coronaviruses, including COVID-19, marking their commitment to addressing global viral challenges. Arbutus's strategic alliances with esteemed organizations such as Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc., along with a clinical collaboration with Barinthus Biotherapeutics plc, underscore their prominent role in the biopharmaceutical landscape.
Products and Services
- Imdusiran (AB-729)
- AB-101
- Small Molecule Antivirals for Coronaviruses
- Clinical Collaboration with Barinthus Biotherapeutics plc to Evaluate VTP-300
A cutting-edge, proprietary RNAi therapeutic that is administered subcutaneously. Imdusiran is targeted at suppressing HBV antigens across the board, including HBsAg, a crucial element in the persistence and replication of the virus in infected individuals. This promising candidate stands at the forefront of Arbutus's HBV pipeline, exemplifying their innovative approach to tackling hepatitis B virus infection.
An oral PD-L1 inhibitor currently under development, AB-101 represents another facet of Arbutus’s therapeutic arsenal against HBV. This novel compound aims to reignite the patient's own HBV-specific immune system, showcasing a unique therapeutic approach by leveraging the body’s inherent defense mechanisms to combat the virus.
In response to the global emergency triggered by the coronavirus pandemic, Arbutus has expanded its research and development to include small molecule antivirals targeting not just HBV but also coronaviruses, including COVID-19. This initiative reflects Arbutus’s flexibility and their commitment to contributing significant solutions to pressing global health crises.
The partnership with Barinthus Biotherapeutics plc to assess VTP-300 signifies a strategic collaboration aimed at discovering potent therapeutic options. This-in-progress evaluation underscores the dedication of Arbutus to explore collaborative opportunities that can enhance their product offerings and potentially lead to novel treatment paradigms.
